Search Results
10
Everything
Search Filters
Organization
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares
January 28, 2025 09:33 ET
|
Medexus Pharmaceuticals Inc
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR...
Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares
January 27, 2025 16:03 ET
|
Medexus Pharmaceuticals Inc
NOT FOR DISTRIBUTION TO UNITED STATES TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has...
Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023 17:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2023 Bloom Burton...
Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
April 11, 2023 07:25 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter...
Medexus Announces New License Deal for Topical Terbinafine
March 22, 2023 07:20 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that the company has secured Canadian rights to commercialize...
Medexus Announces US$58.5 million in New Credit Facilities
March 08, 2023 17:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO. The...
Medexus to Participate in 35th Annual Roth Conference
March 06, 2023 08:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth...
Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022
February 08, 2023 17:00 ET
|
Medexus Pharmaceuticals Inc
Results reflect growth across all leading prescription products, demonstrating continued track record of strong overall performance Management to host conference call at 8:00 AM Eastern Time on...
Medexus Welcomes Two New Board Members
February 06, 2023 17:00 ET
|
Medexus Pharmaceuticals Inc
Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors Appointments bolster Medexus board’s medical and financial expertise, particularly in the United States ...
Medexus Secures Public Reimbursement for Cuvposa® in Quebec
February 01, 2023 17:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the...